Main Menus
Make cash!
| ChristopherSt.. Articles: 6 | |
| ToddMartin Articles: 19 | |
| sharewaremsin Articles: 6 | |
| PeterWilson Articles: 17 | |
| AmyNutt Articles: 61 | |
This article is licensed under a Creative Commons Attribution-No Derivative Works 3.0 Unported License, which means you may freely reprint it, in its entiretly, provided you include the author's resource box along with LIVE links (without "nofollow" tags).
View PDF | Print View | Html Version
by: Stephen Jones
Total views: 27
Word Count: 244
As a major target for dopamine-activated adenylyl cyclase
and protein kinase A in the striatum, DARPP-32 plays a central role in
regulating the efficacy of dopaminergic neurotransmission and can act either as
a phosphatase or kinase inhibitor in a contextually dependent manner. Growing
evidence points to DARPP-32 as a key mediator/modulator in numerous signal
transduction cascades implicated in a growing number of neurological disorders
such as schizophrenia and depression, as well as in drug abuse and
addiction. For example, it has been
shown that acute exposure of mice to cocaine increases phosphorylation of
DARPP-32 at Thr34 with a concommitment decrease in phosphorylation at Thr75,
whereas chronic exposure leads to a reversal of this phospho profile. It has also been observed that many
schizophrenic patients show decreased levels of DARPP-32 in the prefrontal
cortex. For More Information About “ DARPP-32” Visit http://www.imgenex.com/emarketing/112707_DARP32/DARP-32_112707_web.htm While the precise role that DARPP-32 plays in these
psychiatric disorders is still being elucidated, the existing body of
literature clearly portrays DARPP-32 as playing a central role in multiple
signaling pathways. Further research
will determine neuronal subpopulations where phosphorylation of DARPP-32 occurs
as well as the functional importance of previously identified phospho sites of
DARPP-32. IMGENEX offers over one-thousand Neuroscience-related
antibodies such as recently cited anti-DARPP-32 (pan and phosphospecific),
Dopamine D1 and D2 Receptors (IHC validated), 5-HT Receptors (such as 5-HT1B),
Adenosine Receptor, NMDA and more!
For More Information About “ DARPP-32”
Visit http://www.imgenex.com/emarketing/112707_DARP32/DARP-32_112707_web.htm